ITGB2 Antibody

What is ITGB2 and what molecular properties should researchers consider when selecting antibodies?

ITGB2 (also known as CD18, Integrin beta-2, or LAD) is an 84.8 kilodalton protein that functions as the beta subunit of leukocyte-specific integrin heterodimers . It plays crucial roles in immune cell adhesion, migration, and signaling by pairing with different alpha subunits (CD11a, CD11b, CD11c, or CD11d) to form functional integrin complexes.

When selecting ITGB2 antibodies, researchers should consider:

• Epitope specificity: Different antibody clones recognize distinct regions of ITGB2, which may affect detection of conformational states or protein interactions

• Applications compatibility: Verify the antibody has been validated for your specific application (WB, FCM, IHC, etc.)

• Species reactivity: Many ITGB2 antibodies are human-specific, though some cross-react with other species

• Clone characteristics: Some clones like IB4 have specific functional properties, such as blocking activity

• Format options: Available in unconjugated form or with various conjugates (PE, FITC) for different applications

For research requiring functional blockade rather than just detection, specialized antibodies like clone IB4 may be particularly valuable as they can interfere with ITGB2-mediated adhesion .

What are the optimal applications for different formats of ITGB2 antibodies?

Different ITGB2 antibody formats are optimized for specific research applications:

When designing multiparameter flow cytometry panels, researchers should select ITGB2 antibody conjugates that complement other markers in the panel, considering brightness hierarchy (use brighter fluorochromes for lower-expressed targets) and spectral compatibility .

For researchers studying ITGB2 in complex tissue environments like tumors, where expression may vary between cell types, multiplexed approaches combining different antibody formats may provide more comprehensive data than single-method approaches.

How can researchers validate ITGB2 antibody specificity for their experimental systems?

Rigorous validation of ITGB2 antibody specificity is crucial for generating reliable experimental data. A comprehensive validation approach should include:

• Positive and negative control samples:

  • Positive controls: Leukocyte populations known to express high levels of ITGB2

  • Negative controls: Cell lines with verified low ITGB2 expression (some NSCLC cell lines like H1299, A549, PC9 show reduced expression)

  • Isotype controls: Match the isotype, host species, and conjugate of the primary antibody

• Genetic validation approaches:

  • siRNA/shRNA knockdown of ITGB2 to confirm signal reduction

  • CRISPR-Cas9 knockout to eliminate signal completely

  • Overexpression systems to confirm increased signal intensity

• Western blot validation:

  • Verify detection of a single band at the expected molecular weight (~84.8 kDa)

  • Check for absence of non-specific bands

  • Use reducing and non-reducing conditions to confirm specificity

• Cross-validation across applications:

  • Compare results across multiple techniques (e.g., flow cytometry, Western blot, IHC)

  • Confirm consistent expression patterns across methodologies

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide or recombinant ITGB2

  • Verify signal elimination or significant reduction

These validation steps are particularly important when studying diseases where ITGB2 expression is altered, such as in NSCLC where its downregulation has been associated with disease progression and inferior prognosis .

What are the key considerations for detecting ITGB2 expression by Western blotting?

Western blotting for ITGB2 requires specific optimization for reliable detection. Based on published protocols, researchers should consider:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors (PMSF) for efficient extraction

  • Process samples quickly to prevent degradation

  • For tissues with lower expression (e.g., NSCLC tumors), increase protein loading (40-50 μg)

• Gel selection and transfer:

  • Use 8-10% SDS-PAGE gels for optimal resolution of the 84.8 kDa ITGB2 protein

  • Transfer to PVDF membranes, which typically provide better protein retention than nitrocellulose

  • Consider using wet transfer systems for larger proteins like ITGB2

• Blocking and antibody incubation:

  • Block membranes with 5% BSA (preferred over milk for phospho-specific detection)

  • Incubate with primary antibody overnight at 4°C for optimal binding

  • Include appropriate loading controls (GAPDH has been validated for ITGB2 normalization)

• Detection optimization:

  • Use enhanced chemiluminescence for sensitive detection

  • For tissues with lower expression, extend exposure times or use more sensitive substrates

  • Consider digital imaging systems for more accurate quantification

• Troubleshooting common issues:

  • Multiple bands: May indicate degradation products or post-translational modifications

  • Weak signal: Increase antibody concentration or protein amount

  • High background: Increase washing steps or decrease antibody concentration

The recommended primer sequences for qRT-PCR validation are: forward 5′-CTCTCTCAGGAGTGCACGAA-3′ and reverse 5′-CCCTGTGAAGTTCAGCTTCTG-3′, with GAPDH as an endogenous control .

How should flow cytometry protocols be optimized for ITGB2 detection on different cell populations?

Flow cytometry is a powerful technique for analyzing ITGB2 expression on cell surfaces, particularly for immune cells. Optimization should address:

• Sample preparation considerations:

  • Analyze fresh samples when possible, as cryopreservation can affect surface marker expression

  • Use enzyme-free dissociation methods for adherent cells to preserve surface epitopes

  • Include viability dyes to exclude dead cells, which can bind antibodies non-specifically

• Antibody panel design:

  • Include markers to identify specific cell populations of interest (e.g., CD3, CD4, CD8 for T cells)

  • Use bright fluorochromes (PE, APC) for ITGB2 if expression is expected to be low

  • PE-conjugated anti-ITGB2 antibodies have been successfully used in multiple studies

• Staining protocol optimization:

  • Titrate antibodies to determine optimal concentration

  • Stain at 4°C to prevent receptor internalization

  • Include Fc receptor blocking reagents to minimize non-specific binding

  • Standard protocol: 20-minute incubation at 4°C followed by washing steps

• Controls and analysis:

  • Include fluorescence minus one (FMO) controls for accurate gating

  • Use median fluorescence intensity (MFI) rather than percent positive for quantifying expression levels

  • Consider analyzing ITGB2 expression in conjunction with activation markers, as expression may change with cellular activation

• Specialized applications:

  • For phospho-flow analysis of ITGB2 signaling, use appropriate fixation and permeabilization protocols

  • For intracellular ITGB2 staining, optimize permeabilization conditions while preserving epitope integrity

Researchers studying ITGB2 in the tumor microenvironment should consider multiparameter approaches that simultaneously analyze tumor cells and infiltrating immune populations to understand the context-specific roles of ITGB2 .

What methodological approaches are recommended for studying ITGB2's role in epithelial-mesenchymal transition (EMT)?

ITGB2 has been implicated in regulating epithelial-mesenchymal transition (EMT), particularly in NSCLC where it suppresses mesenchymal markers and promotes epithelial phenotypes. To investigate this relationship, researchers should consider:

• Molecular analysis approaches:

  • Perform parallel analysis of ITGB2 and key EMT markers (E-cadherin, N-cadherin, Vimentin, Slug, Snail, Twist)

  • Use qRT-PCR to quantify mRNA expression changes

  • Employ Western blotting to assess protein expression levels

  • Conduct immunofluorescence to visualize subcellular localization

• Genetic manipulation experiments:

  • Overexpress ITGB2 in cell lines with low endogenous expression

  • Knockdown ITGB2 in cells with higher expression

  • Perform rescue experiments to confirm specificity

  • Analyze resulting changes in EMT marker expression and cellular phenotypes

• Functional assays:

  • Migration assays (wound healing, Transwell)

  • Invasion assays (Matrigel-coated Transwell)

  • Adhesion assays to various extracellular matrix components

  • 3D culture systems to assess morphological changes

• Signaling pathway analysis:

  • Investigate canonical EMT regulatory pathways (TGF-β, Wnt/β-catenin)

  • Assess phosphorylation states of key signaling intermediates

  • Use pathway inhibitors to identify critical nodes

• Correlation with clinical data:

  • Analyze ITGB2 and EMT marker expression in patient samples

  • Correlate expression patterns with clinical outcomes

  • Use bioinformatic approaches (GSEA) to identify enriched pathways

Research has demonstrated that ectopic expression of ITGB2 significantly inhibits the proliferation and metastasis of NSCLC cells by suppressing mesenchymal markers (N-cadherin, Vimentin, Slug, Snail, Twist) while promoting E-cadherin expression . These findings suggest that ITGB2-targeted approaches might be valuable for modulating EMT in cancer contexts.

How does ITGB2 expression correlate with immune cell infiltration in tumor microenvironments?

ITGB2 expression has significant implications for immune cell infiltration within tumor microenvironments. Recent studies have revealed:

• Correlation with specific immune populations:

  • ITGB2 expression positively correlates with regulatory T cell (Treg) infiltration in NSCLC

  • Myeloid-derived suppressor cell (MDSC) presence also shows positive correlation with ITGB2 expression

  • These correlations suggest a complex role in immune regulation that may be context-dependent

• Methodological approaches for investigation:

  • Bioinformatic analysis using databases like TCGA to correlate ITGB2 with immune cell signatures

  • Multiplexed immunohistochemistry to simultaneously visualize ITGB2 and immune cell markers

  • Flow cytometry to quantify ITGB2 expression on specific immune populations

  • Single-cell RNA sequencing to identify cell type-specific expression patterns

• Functional implications:

  • As an integrin subunit involved in cell adhesion, ITGB2 may directly influence immune cell migration

  • Its expression on both immune cells and potentially tumor cells creates complex interaction networks

  • The balance between pro-inflammatory and immunosuppressive populations may determine the net effect

• Research considerations:

  • Distinguish between ITGB2 expression on tumor cells versus infiltrating immune cells

  • Consider temporal dynamics of immune infiltration in relation to ITGB2 expression

  • Evaluate how alterations in ITGB2 expression affect different immune populations

Understanding these relationships is particularly relevant for immunotherapy approaches, as ITGB2-mediated immune cell infiltration patterns could influence response to immune checkpoint inhibitors or other immunomodulatory treatments .

What approaches should researchers use to investigate conflicting roles of ITGB2 across different cancer types?

ITGB2 appears to play divergent roles across cancer types, functioning as a tumor suppressor in some contexts while potentially promoting progression in others. To reconcile these conflicting roles, researchers should:

• Conduct comparative multi-cancer analysis:

  • Systematically analyze ITGB2 expression across cancer types using genomic databases

  • Compare expression with clinical outcomes in multiple cancer cohorts

  • Use consistent methodologies when studying different cancer models

  • Identify cancer-specific co-expression patterns that might explain functional differences

• Investigate context-specific molecular mechanisms:

  • Analyze ITGB2 binding partners in different cancer types

  • Identify cancer-specific signaling pathways activated downstream of ITGB2

  • Examine post-translational modifications that might alter function

  • Consider the influence of tumor microenvironment on ITGB2 activity

• Implement comprehensive experimental designs:

  • Study both gain-of-function and loss-of-function effects in multiple cancer cell lines

  • Use orthotopic models to maintain appropriate tissue context

  • Employ syngeneic models with intact immune systems when studying immunological aspects

  • Consider patient-derived xenografts to better recapitulate tumor heterogeneity

• Examine cell type-specific effects:

  • Distinguish between ITGB2 expression on tumor cells versus stromal/immune cells

  • Use conditional knockout models for cell type-specific deletion

  • Employ co-culture systems to study intercellular interactions

• Consider disease stage and progression:

  • Evaluate ITGB2's role at different stages of cancer development

  • Examine effects on primary tumor growth versus metastatic spread

  • Analyze temporal changes in expression during disease progression

In NSCLC, ITGB2 appears to function as a tumor suppressor, with decreased expression in tumor tissues compared to normal tissues and association with inferior prognosis . This finding highlights the importance of cancer-specific analyses rather than generalizing ITGB2's function across all cancer types.

How can researchers use ITGB2 antibodies to investigate signaling pathway interactions?

ITGB2-mediated signaling involves complex interactions with multiple pathways. To effectively investigate these signaling networks, researchers should:

• Phosphorylation analysis approaches:

  • Western blotting with phospho-specific antibodies to detect activation of downstream pathways

  • Phospho-flow cytometry for single-cell analysis of signaling events

  • Phosphoproteomic analysis to identify novel phosphorylation targets

  • Time-course experiments to capture signaling dynamics

• Protein-protein interaction studies:

  • Co-immunoprecipitation with ITGB2 antibodies to identify binding partners

  • Proximity ligation assays to visualize protein interactions in situ

  • FRET/BRET approaches to detect direct protein associations

  • Mass spectrometry of immunoprecipitated complexes for unbiased interaction screening

• Pathway perturbation strategies:

  • Use pathway inhibitors in conjunction with ITGB2 manipulation

  • Implement CRISPR screens to identify synthetic lethal interactions

  • Combine ITGB2 antibodies with stimulatory or inhibitory agents

  • Analyze adaptation mechanisms following prolonged pathway modulation

• Integration with genomic approaches:

  • Correlate signaling activities with transcriptional changes

  • Perform Gene Set Enrichment Analysis (GSEA) to identify enriched pathways

  • Use databases like ComPPI to explore integrated protein-protein interaction networks

  • Apply systems biology approaches to model signaling networks

• Functional validation:

  • Connect signaling events to phenotypic outcomes (proliferation, migration, etc.)

  • Use rescue experiments with constitutively active downstream effectors

  • Implement optogenetic approaches for temporal control of signaling events

  • Correlate in vitro findings with patient-derived data

Gene set enrichment analysis has shown that ITGB2 expression is associated with immune processes and cell adhesion pathways in NSCLC . Researchers should consider these established connections when designing experiments to investigate novel signaling interactions.

What are common troubleshooting issues with ITGB2 antibodies and their solutions?

Researchers working with ITGB2 antibodies commonly encounter several technical challenges that require specific troubleshooting approaches:

• Western blotting issues:

  • Problem: Weak or absent signal
    Solutions: Increase protein loading (40-50 μg for low-expressing samples); extend primary antibody incubation to overnight at 4°C; use more sensitive detection reagents; check for proper transfer with reversible staining

  • Problem: Multiple bands
    Solutions: Verify sample integrity (add protease inhibitors); optimize reducing conditions; try different antibody clones targeting different epitopes; check for known splice variants

• Flow cytometry challenges:

  • Problem: Poor separation between positive and negative populations
    Solutions: Titrate antibody to optimal concentration; use brighter fluorochromes; include Fc receptor blocking; ensure samples are properly processed to preserve surface epitopes

  • Problem: High background staining
    Solutions: Include proper blocking steps; use viability dyes to exclude dead cells; optimize washing steps; validate using FMO controls

• Immunohistochemistry difficulties:

  • Problem: Weak staining in FFPE tissues
    Solutions: Optimize antigen retrieval (test both citrate and EDTA buffers); try different antibody clones; use signal amplification systems; extend primary antibody incubation

  • Problem: Non-specific background
    Solutions: Increase blocking time; dilute primary antibody; add detergent to washing buffers; include serum from the same species as the secondary antibody

• Immunoprecipitation challenges:

  • Problem: Poor pull-down efficiency
    Solutions: Test different lysis buffers; increase antibody amount; extend incubation time; use protein A/G beads suitable for antibody isotype

  • Problem: Co-immunoprecipitation failing to capture interacting partners
    Solutions: Use gentler lysis conditions; consider crosslinking approaches; optimize salt concentration in wash buffers

• Antibody specificity concerns:

  • Problem: Signal in presumed negative controls
    Solutions: Validate with genetic approaches (siRNA, CRISPR); perform peptide competition assays; test multiple antibody clones; include isotype controls

When working with NSCLC samples, researchers should be particularly attentive to sensitivity issues, as ITGB2 expression is typically downregulated in tumor tissues compared to normal tissues .

How can researchers optimize ITGB2 antibody-based immunohistochemistry protocols for different tissue types?

Immunohistochemistry (IHC) with ITGB2 antibodies requires specific optimization for different tissue types:

• Tissue-specific fixation considerations:

  • FFPE tissues: Standard 10% neutral buffered formalin fixation typically preserves ITGB2 epitopes

  • Fresh frozen tissues: May provide better epitope preservation but poorer morphology

  • Adapt fixation times based on tissue density (longer for dense tissues like lung)

  • For NSCLC studies, compare tumor areas with adjacent normal tissue as internal control

• Antigen retrieval optimization:

  • Test both heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0): Often effective for many ITGB2 epitopes

    • EDTA buffer (pH 9.0): May provide better retrieval for certain epitopes

  • Optimize retrieval time: Start with standard protocols (20 minutes) and adjust as needed

  • Consider pressure cooker methods for more consistent results

• Antibody selection and dilution:

  • Primary antibody selection: Choose antibodies validated specifically for IHC applications

  • Titrate antibodies starting from manufacturer's recommended dilution

  • For tissues with lower ITGB2 expression (like NSCLC tumors), start with higher concentrations

  • Consider overnight incubation at 4°C for improved sensitivity

• Detection system optimization:

  • Polymer-based detection systems typically offer better sensitivity than avidin-biotin methods

  • For low expression, consider amplification steps (tyramide signal amplification)

  • Balance signal strength with background: more sensitive systems may require more stringent blocking

• Tissue-specific controls:

  • Positive control tissues: Include immune cell-rich tissues (lymph node, spleen) as ITGB2 is highly expressed in leukocytes

  • Negative control tissues: Include tissues known to have minimal ITGB2 expression

  • Technical controls: Include no-primary-antibody controls and isotype controls

• Quantification approaches:

  • Develop consistent scoring methods (H-score, percentage positive cells, intensity scoring)

  • Consider digital image analysis for more objective quantification

  • For comparative studies, ensure consistent protocol application across all samples

When studying NSCLC, researchers should be aware that ITGB2 expression is typically lower in tumor tissues compared to normal lung tissues, requiring optimized protocols for accurate detection and quantification .

What are key considerations when interpreting discrepancies between mRNA and protein expression data for ITGB2?

Researchers often encounter discrepancies between ITGB2 mRNA and protein expression levels. Properly interpreting these differences requires consideration of several biological and technical factors:

• Biological mechanisms explaining discrepancies:

  • Post-transcriptional regulation: miRNAs may target ITGB2 mRNA

  • Translational efficiency: Variations in translation rates affect protein levels

  • Protein stability: Differences in protein turnover rates

  • Protein trafficking: Surface vs. intracellular pools of ITGB2

  • Alternative splicing: Variants may not be detected by all antibodies

• Technical considerations:

  • Different sensitivities of detection methods: qRT-PCR vs. Western blot vs. flow cytometry

  • Primer design and antibody epitope locations may detect different variants

  • Reference gene or loading control selection affects normalization

  • Sample preparation differences between RNA and protein extraction

• Validation approaches:

  • Use multiple methodologies to confirm expression levels

  • For mRNA: Validate qRT-PCR with different primer sets or RNA-seq

  • For protein: Compare Western blot with flow cytometry or IHC

  • Perform time-course experiments to detect potential delays between transcription and translation

• Interpretation framework:

  • When mRNA is high but protein is low:

    • Consider increased protein degradation or translational inhibition

    • Examine potential post-transcriptional regulatory mechanisms

  • When protein is high but mRNA is low:

    • Consider increased protein stability

    • Verify antibody specificity

    • Check for post-translational modifications that may alter detection

In NSCLC research, studies have reported concordant downregulation of ITGB2 at both mRNA and protein levels in tumor tissues compared to normal tissues . This consistency suggests that transcriptional regulation may be the primary mechanism controlling ITGB2 expression in this context, though researchers should still validate findings using multiple methodologies.

What emerging technologies could enhance ITGB2 research in cancer and immune contexts?

Several cutting-edge technologies are poised to advance ITGB2 research in both cancer biology and immunology:

• Single-cell analysis approaches:

  • Single-cell RNA sequencing can reveal heterogeneity in ITGB2 expression within tumors

  • Single-cell proteomics enables analysis of protein expression and modification at individual cell level

  • Spatial transcriptomics preserves tissue context while providing expression data

  • These technologies can help resolve the complex interplay between tumor cells and immune populations expressing ITGB2

• Advanced imaging technologies:

  • Super-resolution microscopy for visualizing ITGB2 clustering and co-localization

  • Multiplexed imaging (Imaging Mass Cytometry, CODEX) for simultaneous detection of multiple markers

  • Intravital imaging to monitor ITGB2-dependent cell migration in vivo

  • Live-cell imaging to track ITGB2 trafficking and interactions in real-time

• CRISPR-based functional genomics:

  • CRISPR activation/inhibition for precise modulation of ITGB2 expression

  • CRISPR screens to identify synthetic lethal interactions with ITGB2

  • Base editing for introducing specific point mutations in ITGB2

  • In vivo CRISPR for tissue-specific manipulation of ITGB2

• Protein interaction and structural approaches:

  • Proximity labeling techniques (BioID, APEX) to identify context-specific ITGB2 interactors

  • Cryo-EM to resolve structures of ITGB2-containing integrin complexes

  • Interactome analysis to map ITGB2 protein networks across cell types

• Advanced in vitro models:

  • Organoid cultures incorporating immune components

  • Organ-on-chip technologies to study ITGB2 in tissue-specific contexts

  • 3D bioprinted models with defined extracellular matrix components

• Computational and systems biology approaches:

  • Integration of multi-omics data to understand ITGB2 regulation

  • Network analysis to identify key nodes in ITGB2-dependent pathways

  • Machine learning to predict ITGB2 function from complex datasets

These technologies, particularly when used in combination, have the potential to resolve the context-dependent roles of ITGB2 in cancer and immune function, potentially leading to novel therapeutic strategies targeting ITGB2 or its downstream effectors.

How might ITGB2 antibody research contribute to developing new cancer biomarkers or therapeutic approaches?

ITGB2 antibody research has significant potential to contribute to both cancer diagnostics and therapeutics:

• Diagnostic and prognostic biomarker development:

  • ITGB2 expression analysis in tumor tissues could serve as a prognostic marker

  • In NSCLC, low ITGB2 expression correlates with inferior prognosis

  • Monitoring ITGB2+ immune cell populations in peripheral blood might predict immunotherapy response

  • Multiplexed analysis of ITGB2 with other markers could create powerful prognostic signatures

• Therapeutic antibody development strategies:

  • Blocking antibodies to inhibit specific ITGB2 interactions

  • Stimulatory antibodies to enhance immune cell function

  • Bispecific antibodies linking ITGB2+ cells to other therapeutic targets

  • Antibody-drug conjugates for targeted delivery to ITGB2-expressing cells

• Immunotherapy enhancement approaches:

  • Modulating ITGB2 to alter immune cell infiltration patterns

  • Combining anti-ITGB2 approaches with checkpoint inhibitors

  • Using ITGB2 expression to predict responsiveness to immunotherapies

  • Targeting ITGB2-mediated immune suppressive populations (Tregs, MDSCs)

• EMT-targeting therapeutic strategies:

  • Since ITGB2 suppresses EMT in NSCLC, therapeutic approaches mimicking or enhancing this function could inhibit cancer progression

  • Combination therapies targeting ITGB2 and EMT pathways

  • Monitoring EMT markers alongside ITGB2 to track treatment response

• Precision medicine applications:

  • Using ITGB2 expression patterns to stratify patients for specific therapies

  • Developing companion diagnostics based on ITGB2 detection

  • Creating patient-derived models to test ITGB2-targeted approaches

• Technical development considerations:

  • Optimization of antibody specificity for therapeutic applications

  • Development of humanized antibodies to minimize immunogenicity

  • Creation of antibody fragments or alternative scaffolds for improved tumor penetration

  • Exploration of combination approaches with existing therapies

The dual role of ITGB2 in tumor cells and immune populations presents both challenges and opportunities for therapeutic development, requiring careful consideration of context-specific effects and potential off-target impacts.